(OVERALL) The University of Michigan Comprehensive Cancer Center (UMCCC) has a distinguished history of scientific excellence, collaboration, and impact. Its mission is to reduce cancer burden and improve cancer outcomes through research, innovation, transdisciplinary collaboration, education, and outreach and engagement. The vision of the UMCCC is that through its focus on team science and research excellence, the UMCCC will be a national leader in prevention, early diagnosis, optimal treatment, and survivorship care for those at risk of or affected by cancer. Founded in 1986 as the matrix cancer center of the University of Michigan (U-M), the UMCCC first received National Cancer Institute (NCI) designation in 1988, and it has been a comprehensive cancer center since 1991. With strong support from the U-M leadership team and the UMCCC community, Eric Fearon, MD, PhD, was appointed as the third UMCCC Director in September 2016. Dr. Fearon has held multiple leadership roles in UMCCC throughout the past two decades, including Deputy Director, AD for Basic Sciences, and Program Co-Leader for Cancer Genetics. The Center provides an organizational framework to promote transdisciplinary cancer research through the development of well-funded basic, translational, clinical, and prevention programs and the development of shared resources. The Cancer Center?s seven research programs includes four basic programs ? Cancer Biology, Cancer Genetics, Cancer Hematopoiesis and Immunology and Developmental Therapeutics; the Translational and Clinical Research Program; and two cancer control and population sciences programs ? Health Behavior and Outcomes and Cancer Epidemiology and Prevention. UMCCC supports 11 Shared Resources and two developing Shared Resources: Biostatistics, Analytics and Bioinformatics; Cell and Tissue Imaging; Experimental Irradiation; Flow Cytometry; Health Communications; Immune Monitoring; Pharmacokinetics; Preclinical Imaging and Computational Analysis; Structure and Drug Screening; Tissue and Molecular Pathology; Transgenic Animal Models; Proteomics (developing); and Single Cell Analysis (developing). The UMCCC has 287 members representing 50 departments and eight schools and colleges across the University of Michigan. The UMCCC was ranked in the top 10 of NCI-funded academic institutions in 2016 and UMCCC members have annual direct funding of over $100 million. The scientific impact of UMCCC research is reflected through the roughly 4400 UMCCC member publications during the 2012-2016 period, including 15% of UMCCC manuscripts published in journals with impact factor >10, and the strong portfolio of cancer-focused grants held by our members. Fostering transdisciplinary collaboration is a key tenet of UMCCC, evidenced by a high degree of intra- (23.7%) and inter-programmatic publications (31.6%). The Medical School has made substantial commitments to UMCCC through space, financial support, and the recognition of cancer programs as a top priority for the institution.

Public Health Relevance

(OVERALL) The University of Michigan Comprehensive Cancer Center (UMCCC) is committed to reducing cancer burden and improving cancer outcomes through research, innovation, transdisciplinary collaboration, education, and outreach. The UMCCC vision is that through its focus on team science and excellence, the UMCCC will be a national leader in prevention, early diagnosis, optimal treatment, and survivorship care for those at risk of or affected by cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-31
Application #
9993284
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
1997-06-01
Project End
2023-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
31
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Fritsche, Lars G; Gruber, Stephen B; Wu, Zhenke et al. (2018) Association of Polygenic Risk Scores for Multiple Cancers in a Phenome-wide Study: Results from The Michigan Genomics Initiative. Am J Hum Genet 102:1048-1061
Haley, Henry R; Shen, Nathan; Qyli, Tonela et al. (2018) Enhanced Bone Metastases in Skeletally Immature Mice. Tomography 4:84-93
Giordano, Thomas J (2018) Genomic Hallmarks of Thyroid Neoplasia. Annu Rev Pathol 13:141-162
McClintock, Shannon D; Colacino, Justin A; Attili, Durga et al. (2018) Calcium-Induced Differentiation of Human Colon Adenomas in Colonoid Culture: Calcium Alone versus Calcium with Additional Trace Elements. Cancer Prev Res (Phila) 11:413-428
Spector, Matthew E; Farlow, Janice L; Haring, Catherine T et al. (2018) The potential for liquid biopsies in head and neck cancer. Discov Med 25:251-257
Wagner, Vivian P; Martins, Manoela D; Martins, Marco A T et al. (2018) Targeting histone deacetylase and NF?B signaling as a novel therapy for Mucoepidermoid Carcinomas. Sci Rep 8:2065
Harvey, Innocence; Stephenson, Erin J; Redd, JeAnna R et al. (2018) Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice. Endocrinology 159:2275-2287
Schuetze, Scott M; Bolejack, Vanessa; Thomas, Dafydd G et al. (2018) Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol 4:814-820
Su, Wenmei; Feng, Shumei; Chen, Xiuyuan et al. (2018) Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. Cancer Res 78:3207-3219
Hosoya, Tomonori; D'Oliveira Albanus, Ricardo; Hensley, John et al. (2018) Global dynamics of stage-specific transcription factor binding during thymocyte development. Sci Rep 8:5605

Showing the most recent 10 out of 1493 publications